# Lorlatinib for Previously Treated ALK-Positive Advanced NSCLC: Primary Efficacy and Safety From a Phase 2 Study in People’s Republic of China

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/lorlatinib-for-previously-treated-alk-positive-advanced-nsclc-primary-efficacy/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Shun Lü,Qing Zhou,Xiaoqing Liu,Yingying Du,Yun Fan,Ying Cheng,Jian Fang,You Lü,Cheng Zhi Huang,Jianying Zhou,Yong Song,Kai Wang,Hongming Pan,Nong Yang,Juan Li,Gongyan Chen,Jianhua Chang,Jiuwei Cui,Zhe Liu,Chunxue Bai,Helong Zhang,Huadong Zhao,Kaiting Zhang,Gerson Peltz,Heyan Li,Yi‐Long Wu |
| Citations | 34 |
| DOI | 10.1016/j.jtho.2022.02.014 |
| Fields | Medicine |
| Open Access | true |
| OA Status | hybrid |
| OA URL | https://doi.org/10.1016/j.jtho.2022.02.014 |
| OpenAlex ID | https://openalex.org/W4220866365 |
| PMID | 35307611 |
| Type | article |
| Year | 2022 |

## Paper authors

- [Nong Yang](https://scholariq.org/researchers/nong-yang-2/)

## Paper journal

- [Journal of Thoracic Oncology](https://scholariq.org/journals/journal-of-thoracic-oncology/)

## Paper primary topic

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)

## Paper topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.